Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is a standard of care for patients with potentially curable esophageal or esophagogastric junctional cancer.[@CR1],[@CR2] Although esophagectomy has a profound impact on both long- and short-term patient health-related quality of life (HRQOL), addition of nCRT to surgery does not jeopardize HRQOL after surgery compared with surgery alone.[@CR3],[@CR4] However, immediately after completion of nCRT (before surgery), patients show a profound drop in HRQOL compared with baseline levels.[@CR3],[@CR5],[@CR6] This deterioration improves after surgery, suggesting that HRQOL is restored in the period between completion of nCRT and surgery.[@CR3],[@CR5] However, the detailed course of HRQOL during and after completion of nCRT is unknown. Such information might have an impact on the timing of surgery, although this is debated. Traditionally, surgery is scheduled 4--6 weeks after completion of nCRT. However, findings have shown that a longer time to surgery (up to 12 weeks) does not endanger oncologic outcome.[@CR7] Increasing the time to surgery allows patients to recover from nCRT and optimize their physical condition before surgery. Furthermore, a longer waiting time to surgery is suggested to increase the pathologically complete response rate (i.e., no viable tumor cells in the resection specimen), which might improve prognostication.[@CR7]

This study aimed primarily to assess the course of HRQOL in the period from the start of nCRT until surgery for patients with locally advanced esophageal or junctional carcinoma.

Methods {#Sec1}
=======

A multicenter prospective cohort study was conducted. Patients with locally advanced esophageal or esophago-gastric junctional cancer, as determined by endoscopic ultrasound, computed tomography (CT) and/or positron emission tomography (PET)-CT, who would be undergoing nCRT according to the ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) regimen (weekly administration of carboplatin and paclitaxel plus 41.4-Gy concurrent radiotherapy) were considered eligible for the study.[@CR1] Patients considered insufficiently fluent in the Dutch language or cognitively unable to understand the questionnaire were excluded. Consecutive patients were recruited before the start of nCRT in the Erasmus MC--University Medical Centre, Rotterdam, and in the Elisabeth-Tweesteden Hospital, Tilburg. The study was approved by the ethics committee of the Erasmus MC (MEC-2016-250).

HRQOL Measurement {#Sec2}
-----------------

Patients were informed about the study by their own physician. Subsequently, patients were asked to participate via telephone by one of the investigators. Participating patients received the self-report questionnaires by mail and were asked by telephone to complete the questionnaire at baseline (before nCRT), at the date of the last nCRT cycle, and every 2 weeks thereafter until the date of surgery, with a maximum follow-up period of 16 weeks after completion of nCRT. All the patients completed the questionnaires themselves and were reminded twice via telephone by one of the investigators during each assessment.

Cancer-related general HRQOL was measured with the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, a validated questionnaire for cancer patients.[@CR8] Esophageal cancer-specific HRQOL was assessed with the EORTC QLQ-OG25, a validated questionnaire for patients with cancer of the esophagus, the esophago-gastric junction, and the stomach.[@CR9] Chemotherapy-induced peripheral neuropathy (CIPN) symptoms were assessed using the EORTC QLQ-CIPN20, a questionnaire designed to elicit patients' experience of symptoms related to CIPN.[@CR10]

Before the start of the study, end points were defined by individual consensus discussion with upper gastrointestinal (GI) surgical oncologists, medical oncologists, and nurse practitioners. One primary end point and one or two secondary end points from each questionnaire were chosen based on the hypothesized impact of nCRT. This led to assignment of physical functioning (EORTC QLQ-C30), odynophagia (EORTC QLQ-OG-25), and sensory symptoms (EORTC QLQ-CIPN20) as primary end points, and to global quality of life, fatigue (both QLQ-C30), weight loss (EORTC QLQ-OG25), and motor symptoms (EORTC QLQ-CIPN20) as secondary end points.

Statistical Analysis {#Sec3}
--------------------

Data were analyzed on an intention-to-treat basis. Pretreatment clinicopathologic characteristics were collected and described. Questionnaire scores were transformed into a 0--100 scale according to EORTC guidelines.[@CR11] Higher scores for functional and global scales (e.g., physical functioning and global quality of life) indicate better HRQOL. Higher scores on symptom scales (e.g., fatigue) indicate worse HRQOL.

Over-time changes in the follow-up measurements were analyzed using mixed modeling analysis, a technique that enables analysis of all completed questionnaires by allowing for inclusion of data from patients with different numbers of completed measurements.[@CR12] Mean over-time differences were described.

Cohen's d (CD) effect sizes based on the beta estimates from the mixed modeling analyses were used to allow for standardized comparison between different end points and to assess clinical relevance of the found effects. The CD values of 0.2, 0.5, and 0.8 indicate small, medium, and large effects, respectively.[@CR13] Effect sizes of 0.5 or larger were defined as clinically relevant.[@CR14]

On an exploratory basis, we investigated the effects of several background variables on the trajectory of HRQOL scores. Because the investigated sample showed variation in timing of surgery, this could have influenced the course of HRQOL.

Some patients (*n* = 29) participated in the diagnostic preSANO trial.[@CR15],[@CR16] In that trial, the patients underwent a clinical response evaluation (CRE) using endoscopy with biopsies, endoscopic ultrasound, and PET-CT 4--6 weeks after nCRT to determine the accuracy of residual disease detection. The patients with residual disease or non-passable tumor during the clinical response evaluation after 4--6 weeks underwent immediate surgical resection, whereas the remaining patients had surgery 10--14 weeks after completion of nCRT.

Patients with (substantial) residual disease after nCRT might experience worse HRQOL after nCRT, which potentially induces a bias. Furthermore, variations in time to surgery can be attributed to patient-related characteristics such as comorbidities or general condition. More vulnerable patients could have a longer time until surgery intentionally. This might negatively influence HRQOL at longer follow-up measurements, so HRQOL may improve more strongly at the later measures if all patients could have been included. Therefore, the study included the presence of residual disease during clinical response evaluation (only for patients who participated in the preSANO trial), comorbidities (Charlson Comorbidity Index), the American Society of Anesthesiology (ASA) score, age, gender, histology, and cT stage in a separate analysis to investigate their potential effect on the course of HRQOL.[@CR17]

As a correction for multiple comparisons, a *p* value lower than 0.006 was considered statistically significant (a Bonferroni correction of 0.05/9 was applied because the main analyses included nine comparisons with pretreatment levels). All *p* values were two-sided. Data were analyzed using SPSS version 24.0 (IBM, Chicago, IL, USA).

Results {#Sec4}
=======

Of 106 eligible patients, 96 (91%) were included from May 2016 through June 2017 (10 patients refused participation). The rates of response to the questionnaires ranged from 78 to 99% (Table [1](#Tab1){ref-type="table"}). The median age of the patients was 68 years (interquartile range \[IQR\], 61--71 years), and 77 (80%) of the patients were men. Most of the patients had cT3 tumor (80%) and suspicious regional lymph nodes (66%; Table [2](#Tab2){ref-type="table"}). Table 1Eligibility status of the study patientsStatusBaselineLast cycle2 Weeks4 Weeks6 Weeks8 Weeks10 Weeks12 Weeks14 Weeks16 WeeksEligible96969696938856494232Total returned questionnaires (% of eligible)95 (99)90 (94)93 (97)92 (96)89 (96)83 (94)51 (91)46 (94)37 (88)25 (78)Surgery (cumulative)00003839465363Deceased0000001111Too ill0411111134Randomly missing/other1223344223Table 2Clinicopathologic characteristics of the study patientsCharacteristic(*n* = 96)\
*n* (%)Age at inclusion (years) Median68 IQR61--71Male sex77 (80)Tumor type Squamous cell carcinoma18 (19) Adenocarcinoma78 (81)Clinical T stage^a^ cT11 (1) cT215 (16) cT377 (80) cT43 (3)Clinical N stage^b^ cN033 (34) cN138 (4) cN219 (20) cN36 (6)ASA classification^c^ 115 (16) 265 (68) 314 (15)Missing2 (2)*IQR* interquartile range, *ASA* American Society of Anesthesiology^a^Clinical tumor (cT) stage was assessed via endoscopic ultrasonography or computed tomography (CT) and classified according to the International Union for Cancer Control (IUCC) tumor-node-metastasis (TNM) classification, 7th ed^b^Clinical lymph-node (*N*) stage was assessed via endoscopic ultrasonography, CT, or 18F-fluorodeoxyglucose positron-emission tomography and classified according to IUCC TNM classification, 7th ed^c^ASA classification is on a scale of 0 to 5, with lower numbers indicating better physical status, 1 indicating a normal healthy patient, 2 indicating a patient with mild systemic disease, and 3 indicating a patient with severe systemic disease

Predefined Primary End Points {#Sec5}
-----------------------------

### Physical Functioning (Fig. [1](#Fig1){ref-type="fig"}a) {#Sec6}

The over-time changes in physical functioning levels were statistically significant (*p* \< 0.001). Physical functioning had declined at the last cycle of nCRT (− 16; *p* \< 0.001; CD − 0.80; 95% confidence interval \[CI\], − 1.00 to − 0.59) compared with the baseline levels. During the follow-up period, physical functioning improved from 2 to 10 weeks after nCRT (4 vs 2 weeks: + 6; *p* \< 0.001; CD 0.30; 95% CI 0.17--0.42; 6 vs 4 weeks: + 6; *p* \< 0.001; CD 0.28; 95% CI 0.17--0.39; 8 vs 6 weeks: +5; *p* \< 0.001; CD 0.24; 95% CI 0.15--0.32; 10 vs 8 weeks: + 3; *p *= 0.003; CD 0.15; 95% CI 0.05--0.24, respectively). From this point, the improvement was no longer statistically significant. Baseline levels were reached at 8 weeks (*p* = 0.95) but were not exceeded during the follow-up period.Fig. 1Mean scores with standard deviations for **a** physical functioning, **b** odynophagia, **c** sensory symptoms (primary end points), **d** global quality of life, **e** fatigue, **f** weight loss, and **g** motor symptoms (secondary end points)

### Odynophagia (Fig. [1](#Fig1){ref-type="fig"}b) {#Sec7}

The over-time changes in odynophagia levels were statistically significant (*p* \< 0.001). Compared with the baseline levels, the odynophagia levels had worsened at the last cycle of nCRT (14; *p* \< 0.001; CD − 0.45; 95% CI 0.20--0.70) and remained at that level 2 weeks after nCRT (*p* = 0.038). Thereafter, the odynophagia levels improved from 2 to 4 weeks (− 21; *p* \< 0.001; CD − 0.69; 95% CI − 0.89 to − 0.49), and from 4 to 6 weeks (− 11; *p* \< 0.001; CD − 0.37; 95% CI − 0.50 to − 0.24). After that, improvement was no longer statistically significant compared with the previous measurement. At 4 weeks after nCRT, baseline levels were reached (*p* = 0.68), and at 6 weeks, the odynophagia levels had improved compared with baseline levels (6 weeks: − 15; *p* \< 0.001; CD − 0.42; 95% CI − 0.64 to − 0.20; 10 weeks: − 24; *p* \< 0.001; CD − 0.77; 95% CI − 0.98 to − 0.57).

### Sensory Symptoms (Fig. [1](#Fig1){ref-type="fig"}c) {#Sec8}

Generally, the over-time changes in sensory symptoms were not statistically significant (*p* = 0.009). However, the specific comparisons between occasions showed that sensory symptoms had worsened at the last cycle of nCRT compared with pretreatment levels, (+4: *p* \< 0.001; CD 0.53; 95% CI 0.28--0.80). At 6 weeks after nCRT, sensory symptoms had returned to baseline levels (*p* = 0.013). No further statistically significant improvement compared with previous measurements was observed.

Predefined Secondary End Points {#Sec9}
-------------------------------

### Global Quality of Life (Fig. [1](#Fig1){ref-type="fig"}d) {#Sec10}

The global quality-of-life scores showed statistically significant changes over time (*p* \< 0.001). At the last cycle of nCRT, the global quality-of-life scores had declined (− 16: *p* \< 0.001; CD − 0.77; 95% CI − 0.96 to − 0.57) and had further worsened 2 weeks thereafter (− 6: *p* = 0.002; CD − 0.29; 95% CI − 0.47 to − 0.11). From 2 to 8 weeks after nCRT, the global quality-of-life levels improved compared with the previous measurement (4 vs 2 weeks: + 11; *p* \< 0.001; CD 0.51; 95% CI 0.33--0.69; 6 vs 4 weeks: + 7; *p* \< 0.001; CD 0.34; 95% CI 0.19--0.49; 8 vs 6 weeks: + 5; *p* = 0.001; CD 0.24; 95% CI 0.10--0.39, respectively). After that, improvement was no longer statistically significant. At 6 weeks after nCRT, baseline levels were reached (*p* = 0.031). The baseline levels were not exceeded during the follow-up period.

### Fatigue (Fig. [1](#Fig1){ref-type="fig"}e) {#Sec11}

Over time, the fatigue levels changed significantly (*p* \< 0.001). Compared with baseline, the fatigue levels had increased at the last cycle of nCRT (+ 34: *p* \< 0.001; CD 1.21; 95% CI 1.04--1.39) and remained stable until 2 weeks after nCRT (*p *= 0.32). After that, improvement was observed until 6 weeks compared with the previous measurements (4 vs 2 weeks: − 15; *p* \< 0.001; CD − 0.57; 95% CI − 0.73 to − 0.41; 6 vs 4 weeks: − 13; *p* \< 0.001; CD − 0.46; 95% CI − 0.60 to − 0.32). Baseline levels were reached at 6 weeks (*p* = 0.007). Thereafter, no statistically significant improvement compared with the previous measurement was observed. Compared with baseline levels, improvement was observed 16 weeks after nCRT (− 8; *p* = 0.001; CD − 0.28; 95% CI − 0.44 to − 0.11).

### Weight Loss (Fig. [1](#Fig1){ref-type="fig"}f) {#Sec12}

The weight loss scores changed significantly over time (*p* \< 0.001). At the last cycle of nCRT, weight loss had worsened compared with baseline levels (+ 10: *p* = 0.002; CD 0.36; 95% CI 0.13--0.58) and did not improve 2 and 4 weeks after nCRT compared with the previous measurement (*p* = 0.263 and 0.038, respectively). The scores then returned to baseline levels 4 weeks after nCRT (*p* = 0.031) and improved further (6 vs 4 weeks: 9; *p* \< 0.001; CD − 0.31; 95% CI − 0.47 to − 0.16; 8 vs 6 weeks: − 7; *p* \< 0.001; CD − 0.24; 95% CI − 0.37 to − 0.12). At 12 weeks after nCRT, the weight loss scores had improved compared with baseline levels (− 15; *p* \< 0.001; CD − 0.52; 95% CI − 0.79 to − 0.26).

### Motor Symptoms (Fig. [1](#Fig1){ref-type="fig"}g) {#Sec13}

The over-time change in motor symptoms was statistically significant (*p* \< 0.001). Motor symptoms had worsened at the last cycle of nCRT (+  4; *p* \< 0.001). At 4 weeks after nCRT, the motor symptoms had returned to baseline levels (*p* = 0.028). No further improvements in motor symptoms compared with previous measurements was observed.

### Other End Points {#Sec14}

The mean scores of HRQOL domains, except for the predefined end points, are presented in Table [3](#Tab3){ref-type="table"}. Table 3Mean scores for all domains in the three European Organization for Research and Treatment of Cancer (EORTC) questionnaires that were not predefined end pointsStatusBaselineLast cycle2 Weeks4 Weeks6 Weeks8 Weeks10 Weeks12 Weeks14 Weeks16 WeeksQLQ-C30 Functional scales  Role82 ± 2356 ± 3250 ± 3226 ± 3071 ± 2779 ± 2381 ± 2281 ± 2582 ± 2585 ± 25  Emotional75 ± 2074 ± 2472 ± 2378 ± 1980 ± 2081 ± 1781 ± 1983 ± 1682 ± 1782 ± 19  Cognitive91 ± 1681 ± 2582 ± 2086 ± 1991 ± 1692 ± 1691 ± 1793 ± 1493 ± 1395 ± 12  Social88 ± 1870 ± 3069 ± 2778 ± 2386 ± 2088 ± 1889 ± 1889 ± 1890 ± 1991 ± 18 Symptom scores  Nausea and vomiting12 ± 2328 ± 3032 ± 3213 ± 2010 ± 195 ± 153 ± 85 ± 115 ± 111 ± 3  Pain14 ± 1932 ± 2838 ± 3122 ± 2614 ± 2011 ± 2012 ± 2211 ± 2112 ± 249 ± 19  Dyspnea8 ± 1620 ± 2622 ± 2620 ± 2612 ± 2111 ± 2111 ± 2113 ± 1911 ± 198 ± 15  Insomnia27 ± 3035 ± 3333 ± 3424 ± 3120 ± 2516 ± 2418 ± 2417 ± 2614 ± 2012 ± 25  Loss of appetite21 ± 2846 ± 3552 ± 3533 ± 3418 ± 2612 ± 2412 ± 2212 ± 2411 ± 217 ± 17  Constipation9 ± 2125 ± 3325 ± 3213 ± 247 ± 165 ± 147 ± 154 ± 134 ± 107 ± 17  Diarrhea6 ± 1716 ± 2615 ± 265 ± 164 ± 125 ± 137 ± 133 ± 94 ± 135 ± 12  Financial worries3 ± 128 ± 226 ± 185 ± 145 ± 175 ± 164 ± 164 ± 134 ± 104 ± 11QLQ-OG25 Symptom scores  Dysphagia27 ± 2541 ± 2856 ± 3025 ± 2516 ± 1913 ± 2110 ± 176 ± 126 ± 154 ± 7  Eating42 ± 2857 ± 2862 ± 2840 ± 3127 ± 2820 ± 2716 ± 2313 ± 2010 ± 179 ± 15  Reflux9 ± 1814 ± 2316 ± 268 ± 215 ± 143 ± 103 ± 123 ± 111 ± 61 ± 7  Pain and discomfort15 ± 2329 ± 2830 ± 3222 ± 2814 ± 2313 ± 2210 ± 19127 ± 177 ± 1710 ± 20  Anxiety52 ± 2546 ± 2647 ± 2743 ± 2541 ± 2743 ± 2642 ± 2641 ± 2239 ± 2636 ± 27  Eating with others27 ± 3334 ± 3536 ± 2621 ± 3011 ± 247 ± 175 ± 125 ± 144 ± 101 ± 7  Dry mouth13 ± 2326 ± 2829 ± 3017 ± 2413 ± 209 ± 2012 ± 2113 ± 279 ± 227 ± 14  Trouble with taste18 ± 3244 ± 3746 ± 3532 ± 3221 ± 2712 ± 2410 ± 208 ± 205 ± 127 ± 17  Trouble swallowing saliva13 ± 2724 ± 3224 ± 3014 ± 267 ± 185 ± 153 ± 113 ± 122 ± 83 ± 9  Choking when swallowing10 ± 229 ± 179 ± 185 ± 143 ± 104 ± 132 ± 94 ± 135 ± 143 ± 9  Trouble with coughing26 ± 2632 ± 2834 ± 2828 ± 2721 ± 2323 ± 2419 ± 2419 ± 2517 ± 2216 ± 17  Trouble talking6 ± 1810 ± 1913 ± 248 ± 183 ± 103 ± 115 ± 134 ± 134 ± 104 ± 11  Hair loss10 ± 2522 ± 2919 ± 2621 ± 2919 ± 3116 ± 2614 ± 2814 ± 3117 ± 365 ± 13QLQ-CIPN20 Autonomic scale11 ± 1521 ± 1922 ± 1918 ± 1814 ± 1614 ± 1514 ± 1514 ± 1614 ± 1814 ± 18Scores are presented as means ± standard deviations

### Influence of Residual Disease, Comorbidities, and General Condition {#Sec15}

Inclusion of residual disease present during the clinical response evaluation, comorbidities (Charlson Comorbidity Index), ASA score, age, gender, histology, and cT stage as control variables did not have an impact on the reported overall trends in HRQOL trajectories (data not shown). However, the patients who had residual disease during CRE exhibited worse odynaphagia levels. The patients with higher Charlson Comorbidity Index (CCI) experienced more fatigue, and the patients with a higher cT stage had more weight loss (Table S1). Furthermore, the patients who had residual disease during CRE or a higher ASA score had increased weight loss over time (Table S2; Fig. S1).

Discussion {#Sec16}
==========

This prospective cohort study showed a profound negative, short-term impact of nCRT on all HRQOL end points for patients who had esophageal or junctional cancer treated with a multimodality regimen based on carboplatin/paclitaxel combined with 41.4 Gy of concurrent radiotherapy. Subsequently, all primary and secondary HRQOL end points were restored to baseline levels 4--10 weeks after completion of nCRT. The odynophagia, fatigue, and weight loss scores even improved after nCRT compared with baseline levels at 6, 16, and 12 weeks, respectively.

This is the first study to investigate the detailed short-term course of HRQOL after nCRT for esophageal or junctional cancer. A previous study showed a negative impact of nCRT on HRQOL 12 weeks after the start of neoadjuvant treatment, which was restored to baseline levels 3 weeks before surgery.[@CR6] However, this earlier study used a small sample (*n* = 34), only two measurements after nCRT with respect to the start of nCRT rather than the end of nCRT, and the date of surgery, hampering precise assessment of the HRQOL trajectory after nCRT. A study using the Functional Assessment of Cancer Therapy-Esophageal (FACT-E) demonstrated findings similar to those in the current study in terms of return to baseline before surgery, but included only patients who had neoadjuvant chemotherapy.[@CR18]

The HRQOL analysis in the CROSS trial also showed a profound deterioration 1 week after completion of nCRT compared with baseline scores for all primary and secondary HRQOL end points (physical functioning, global quality of life, fatigue, eating, and emotional functioning). However, this study lacked extra measurements between the end of nCRT and the date of surgery.[@CR3]

The results of the current study underscore the value of sufficient recuperation time between completion of nCRT and esophagectomy to enable patients to undergo surgery in optimal physical condition, potentially improving surgical outcome. Moreover, delayed surgery tends to increase the pathologically complete response rate, potentially improving prognosis.[@CR7],[@CR19] We recommend that timing of surgery be guided by the patient's condition. It is advocated that surgery be postponed to as long as 12 weeks after completion of nCRT, and even longer than that when patients experience persisting adverse events or are in bad general condition, especially in the absence of residual disease.

Previous studies have shown lasting deterioration of HRQOL after multimodality treatment for patients with esophageal cancer.[@CR4],[@CR20]--[@CR22] Given the current results, these negative findings likely are attributable to esophagectomy and not to chemoradiotherapy per se. Definitive chemoradiotherapy without esophagectomy circumvents the adverse effects of surgery. However, the long-term oncologic outcome is suggested to be inferior to (nCRT plus) surgery.[@CR23]

An active surveillance strategy after completion of nCRT is a topic of investigation in the ESOSTRATE and Surgery As Needed for Oesophageal cancer (SANO) trials.[@CR15],[@CR24] With this novel treatment strategy, patients undergo frequent clinical examinations after completion of nCRT, and esophagectomy is offered only to patients with a histologically proven or highly suspected locoregional regrowth without signs of distant dissemination. This active surveillance strategy might reduce the number of patients who need esophagectomy by 30--40%, reducing the impact of surgery on HRQOL. The results of the current study can be used to inform patients for whom a future active surveillance strategy is considered because the stable HRQOL levels during the last measurements likely reflect the HRQOL levels during active surveillance.

The limitations of the current study included the differences in timing of surgery between patients, which introduced different follow-up periods between patients. Nevertheless, inclusion of the confounders, namely, the presence of residual disease during clinical response evaluation (only patients in the preSANO trial), comorbidities (Charlson Comorbidity Index), and ASA score, did not influence the overall trends in HRQOL trajectories.

Another limitation was the potential effect of response shift or reconceptualization of symptoms during treatment (i.e., what was bad before is the new normal). Unfortunately, this is inevitable in HRQOL studies.

In conclusion, HRQOL decreased substantially after completion of nCRT for esophageal cancer, but was restored to baseline levels for all end points within 10 weeks. Odynophagia, fatigue, and weight loss had improved within 16 weeks after nCRT compared with baseline levels. These results suggest a benefit of delaying surgery, especially for vulnerable patients, and can be used to inform patients for whom a future active surveillance strategy is considered.

Electronic supplementary material
=================================

 {#Sec17}

Below is the link to the electronic supplementary material. Supplementary material 1 (DOCX 72 kb)

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

There are no conflicts of interest.
